Press Release | May 21, 2023

LEO Pharma & Minapharm sign an exclusive agreement in Egypt

LEO Pharma & Egypt’s Minapharm expand a longstanding strategic manufacturing partnership of three decades. The successful long-term brands Fucidin® and Fucicort® account for dominant market shares in their categories. The new agreement further adds commercialization of a full portfolio of innovative dermatologic therapeutics for treatment of psoriasis and atopic dermatitis to fulfill unmet medical needs of patients across Egypt, a country that remains among the largest consumers of pharmaceuticals in the Middle East and Africa.

This agreement is in line with LEO Pharma’s strategy of building a simple yet competitive organizational model that extends to Minapharm’s advanced manufacturing capabilities for further providing high-quality, innovative solutions.

The two companies seek to solidify brand presence and improve patient health outcomes in the region. Minapharm’s experienced teams and broad distribution networks will ensure LEO Pharma products reach modern trade, traditional trade, hospitals, clinics, and other medical channels, reinforcing their accessibility by all patients in need across the country.

“Signing this agreement is a pinnacle of collaboration following three decades of manufacturing LEO’s flagship dermatology products. It further expands the business with a portfolio of novel skin therapeutics and unfolds future business opportunities.” says Dina Soliman, Director of Strategic Operations and Business Development of Minapharm Pharmaceuticals.

“Strong partnerships are a key element in our strive to building a more simple and competitive LEO Pharma. On this journey, we are happy to extend our already long-lasting partnership with Minapharm and secure patients in Egypt continued access to our medicines” says Khalid Aouidat, Vice President Rest of World of Leo Pharma.

About Minapharm

Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically-engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly owned Berlin-based subsidiary, ProBioGen AG, Minapharm has established an integrated business model making it to-date the only gene-to-market biopharmaceutical company in the region. Minapharm employs a collective workforce of over 1700 and is listed on the Cairo and Alexandria stock exchange (Symbol: MIPH).

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.